SCM
PACB icon

Sandler Capital Management’s Pacific Biosciences PACB Stock Holding History

Sandler Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-130,000
Closed -$4.33M – 121
2021
Q1 		$4.33M Buy
+130,000
New +$4.55M 0.37% 91

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sandler Capital Management's PACB Position: Q2 2021 in Review

Sandler Capital Management sold out of Pacific Biosciences (PACB) in Q2 2021, closing a stake of 130,000 shares — an estimated $4.33M sold.

Sandler Capital Management first reported a position in PACB in Q1 2021 and held it in 1 quarter. The position peaked at $4.33M in Q1 2021. 262 funds tracked by Wall St. Rank hold PACB as of Q2 2021.

  • Sandler Capital Management reported no remaining Pacific Biosciences position as of Q2 2021 after selling out during the quarter.
  • Sandler Capital Management sold 130,000 Pacific Biosciences shares in Q2 2021, an estimated $4.33M.
  • Sandler Capital Management first reported a position in Pacific Biosciences in Q1 2021 and held it in 1 quarter.
  • Sandler Capital Management's Pacific Biosciences position peaked at $4.33M in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2021.

Based on Sandler Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.